Polypeptide With Localisation/Targeting Motif TRIZ Cases

Engineered chimeric phagocytic receptors enhance microglial clearance of toxic protein aggregates in the central nervous system.

Recombinant expression vectors enhance leghemoglobin production in engineered Escherichia coli strains using specific signal peptides.

Truncated CD93 protein inhibits osteoclasts, correcting the imbalance between bone resorption and formation to increase mineral density.

NKp46 and NKp44 peptide fragments target viral-infected and tumor cells, resolving the trade-off between structural complexity and binding reliability.

Cell cycle-regulated Cas9 degradation increases homology-directed repair frequency while reducing off-target mutations.

Composite transcription factors bypass Adeno-associated virus packaging capacity limits while maintaining high therapeutic efficacy.

Engineered Cas9 enzymes with specific amino acid substitutions alter binding kinetics to enhance gene editing precision.

A chimeric antigen receptor integrates a cytokine receptor activating domain to enhance T-cell activation and persistence.

Integrating a suicide gene with CAR and FOXP3 into nucleic acid constructs enables selective cell deletion to prevent cytokine storms.

Specific VprBP kinase inhibitors block carcinogenic potential by reducing H2AT120 phosphorylation, activating tumor suppression functions.

Mutating the DAP10 cytoplasmic domain reduces T cell exhaustion and toxicities while improving anti-tumor efficacy.

Peptide inhibitors block eNOS and β-actin association, reducing reactive oxygen species production during hyperoxia therapy.

A murine anti-CD19 chimeric antigen receptor uses a 4-1BB costimulatory domain to boost T cell cytotoxicity.

Recombinant fusion proteins enable precise apoptotic cell detection through site-specific fluorophore autoconjugation.

A chimeric activation receptor featuring a TGFβ-binding domain and CD2 costimulatory domain converts inhibitory signals into stimulatory immune responses.

Chimeric antigen receptors bind TIM-1 to direct cytotoxic cells toward cancer, bypassing immunosuppressive microenvironments.

Frame-slip motifs reduce interleukin 12 secretion, enabling CAR-T cells to persist in hostile tumor microenvironments.

Engineered arenavirus vectors split viral open reading frames across multiple mRNA transcripts to enhance genetic stability and transgene expression.

Extended tandem repeats in modified lubricins increase intra-articular half-life to resolve insufficient lubrication durability.

Chimeric molecules cluster endogenous T-cell receptors to deliver costimulatory signals, overcoming insufficient tumor ligand availability.

A microfluidic device isolates patient-specific B cells from tumor samples to identify cancer-targeting antibodies.

Intratumoral plasmid electroporation merges cytokine and co-stimulatory gene delivery to resolve insufficient tumor regression in melanoma treatment.

Segmented PfRH5 antigens eliminate non-protective chains to resolve the trade-off between antibody effectiveness and unwanted side effects.

Dual CAR T cells targeting GD2 and GD3 overcome neuroblastoma heterogeneity while cytokine enhancement improves persistence.

Removing the Notch regulatory region eliminates membrane force sensitivity while preserving ligand detection precision.

Peptide linkers fuse accessory proteins to Cas9, resolving the trade-off between detection capability and editing activity.

Segmented antibody fragments penetrate living cells to deliver anticancer agents, resolving the trade-off between binding reliability and membrane permeability.

Fusion protein strategy boosts insulin aspart expression levels, resolving weak yeast productivity and simplifying purification.

Segmenting the nuclease complex into separate guide and protein parts resolves purification difficulties while maintaining high editing efficiency.

Administering beraprost before infusion prevents dangerous cytokine release syndrome while preserving anti-tumor efficacy.

A PD1-4-1BBL fusion protein binds PDL1 and 4-1BB to co-stimulate immune cells.

A recombinant protein fusion induces direct somatic embryogenesis in Cannabis sativa L. liquid culture.

Novel adenine base editors utilize adenosine deaminase variants fused to programmable DNA binding domains for precise nucleobase modification.

An RNA-scaffold mediated base editing system modifies immune cell genomes with high specificity.

RNA-guided CRISPR-Cas effector proteins and ribonucleoprotein complexes enable precise nucleic acid modification through specific guide RNA binding.

Fluorescent conjugates identify tumor antigens to resolve specificity and complexity trade-offs in personalized CAR T-cell therapy.

Fully human ROR1 chimeric antigen receptors evade anti-CAR immunity to sustain T cell persistence and cytolytic activity against solid tumors.

A cell-permeable peptide interrupts radixin binding to alpha5GABAA receptors.

Merging zinc finger DNA binding with p300 HAT domains overcomes global acetylation limits to achieve specific gene regulation.

Human anti-CD19 antibodies reduce immunogenicity while maintaining binding affinity to treat B cell malignancies.

A chimeric lysosomal acid lipase with an optimized heterologous signal peptide increases enzyme secretion from modified hematopoietic stem cells.

IL13Ra2-targeting chimeric antigen receptors bind to glioblastoma cells, reducing tumor growth in brain cancer models.

Engineered vector uses LoxP sites and cleavable peptides to express distinct antigen-binding domains, reducing antigen escape risk in tumor treatment.

An enzymatic ligation system couples molecular catchers to cell surfaces, resolving competitive displacement issues during high-affinity biomolecule selection.

Monoclonal antibodies bind human mesothelin to prevent shedding, thereby maintaining immunotherapy effectiveness against resistant tumors.

Engineered IL-13Rα2 CARs improve solid cancer therapy by resolving low targeting efficacy through specialized scFv binding.

Fc-fused TCRs target mutated KRAS peptides while avoiding wild-type cross-reactivity.

Segmented expression cassettes with destabilizing elements resolve toxicity and surveillance trade-offs in CAR T-cell therapies.

Secreted IL-18 reverses immunosuppressive tumor microenvironments, reducing growth and toxicity in solid tumors.